A novel amino acid agent could zero in on cancerous tumors and provide a much longer half-life than the status quo, according to a study published in the April issue of the Journal of Nuclear Medicine. {read more here}

Partners Healthcare just released a list of what it ranks the top dozen most promising approaches in neurocare. Here’s that dozen, populated with useful links that inform the direction academia – and business – are headed. They’ve been vetted, and it’s confirmed: These trends truly are on the bleeding edge of research. {read more here}

Brain metastases are common in human epidermal growth factor receptor (Her)-2-positive breast cancer. Drug access to brain metastases and normal brain is key to management of cranial disease.  In this study, positron emission tomography (PET) scanning after administration of radiolabelled lapatinib was used to obtain direct evidence of cranial drug access. {read more here}

Positron emission tomography (PET), sophisticated scans pioneered in Victoria, that use small amounts of radioactive material to make the plaque build-up glow have recently shown it’s possible to detect Alzheimer’s disease 15-20 years before people experience symptoms, providing hope that if the plaque build-up is caught early it could slow or even stop brain cell death. {read more here}